Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Frequently asked questions
What sector does Outlook Therapeutics, Inc. (41O) operate in?
Outlook Therapeutics, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Outlook Therapeutics, Inc. (41O) current stock price?
As of the latest data, Outlook Therapeutics, Inc. stock price is €0.45, with a previous close of €0.45. Outlook Therapeutics, Inc. lost -€0.00 in the last trading session, representing a -0.58% loss.
What is Outlook Therapeutics, Inc. (41O) current market capitalization?
Outlook Therapeutics, Inc. market cap is approximately 108.67 million.
What is Outlook Therapeutics, Inc. (41O) Earnings Per Share (EPS)?
The trailing EPS is -€0.60.
What is Outlook Therapeutics, Inc. (41O) EBITDA?
Outlook Therapeutics, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -9.45 million.
Does Outlook Therapeutics, Inc. (41O) pay dividends?
No. Outlook Therapeutics, Inc. does not pay a dividend.
When is Outlook Therapeutics, Inc. (41O) next earnings report?
Outlook Therapeutics, Inc. is expected to release its next earnings report on September 30, 2026.
What is Outlook Therapeutics, Inc. (41O) beta (volatility) score?
Outlook Therapeutics, Inc. has a beta of 0.674, indicating lower volatility than the overall market.
